View More Recent Stories

Mar 10, 2025 07:30AM Plus Therapeutics (PSTV) Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Mar 7, 2025 07:30AM Plus Therapeutics (PSTV) Announces Publication Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Mar 6, 2025 07:32AM Plus Therapeutics (PSTV) Granted FDA Orphan Drug Designation for Rhenium Obisbemeda
Mar 4, 2025 02:13PM Plus Therapeutics (PSTV) Announces $15M Private Placement
Feb 26, 2025 07:30AM Plus Therapeutics (PSTV) Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Feb 24, 2025 07:31AM Plus Therapeutics (PSTV) Announces Leadership Appointments for CNSide Diagnostics Subsidiary
Feb 20, 2025 07:30AM Plus Therapeutics (PSTV) Appoints Michael Rosol as Chief Development Officer
Feb 18, 2025 07:30AM Plus Therapeutics (PSTV) Secures $5.7M Financing to Support Leptomeningeal Metastases Program
Dec 17, 2024 07:30AM Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data
Dec 3, 2024 07:31AM Plus Therapeutics (PSTV) Expands Strategic Agreement with Telix IsoTherapeutics
Nov 26, 2024 07:07AM H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)
Nov 25, 2024 07:31AM Plus Therapeutics (PSTV) Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases
Nov 22, 2024 07:32AM Plus Therapeutics (PSTV) to Present Positive FORESEE Clinical Trial Summary
Nov 18, 2024 07:22AM Plus Therapeutics Inc. (PSTV) PT Lowered to $10 at Jones Trading
Nov 15, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on Plus Therapeutics Inc. (PSTV)
Nov 14, 2024 09:54PM Plus Therapeutics (PSTV) Misses Q3 EPS by 37c
Nov 6, 2024 07:30AM Plus Therapeutics (PSTV) and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
Oct 4, 2024 04:16PM Plus Therapeutics (PSTV) Files $100M Mixed Shelf
Oct 1, 2024 07:30AM Plus Therapeutics (PSTV) Reports ReSPECT-GBM Clinical Trial Update
Sep 18, 2024 07:30AM Plus Therapeutics (PSTV) Showcases New Interim ReSPECT-GBM Phase 2 Trial Data
Sep 3, 2024 06:49AM Plus Therapeutics Inc. (PSTV) PT Lowered to $20 at Ascendiant Capital
Aug 14, 2024 05:17PM Plus Therapeutics (PSTV) Misses Q2 EPS by 71c
Aug 13, 2024 07:30AM Plus Therapeutics (PSTV) Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Aug 12, 2024 07:30AM Plus Therapeutics (PSTV) Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
Jun 24, 2024 04:10PM Plus Therapeutics (PSTV) Files for 10.77M Share Offering by Selling Stockholders
View More Recent Stories